It has also been reported in the literature that the use of angiotensin converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) reduces hemoglobin (Hb) levels in various patient groups at risk for secondary erythrocytosis/polycythemia [4–6]. The gene discussed is ACE; the disease is polycythemia.